Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New Equine Virus test launched
NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms.
Test to prevent misdiagnosis of often fatal disease

The first commercial diagnostic test for New Equine Virus (NEV) has been launched.

First discovered in 2013, NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms, such as anaemia and neurological problems.

It is most often confused with the Swamp Fever virus (EIAV) and Equine Herpesvirus (EHV).

Now, thanks to research by equine biotech firm Equigerminal, vets, laboratories and horse owners will be able to identify this often fatal disease and administer the appropriate treatment.

The test requires a vet to take a blood sample from the horse and send it to the Equigerminal lab. The blood is then analysed and the results are returned to the owner or vet.

When the results are returned, the horse can be given treatment and the spread of the disease can be prevented. Currently, treatment is aimed towards improving the general wellbeing of the horse, monitoring its health and boosting the immune system.

NEV was discovered by Portuguese scientist and veterinary surgeon Isabel Fidalgo Carvalho while completing her PhD in Equine Sciences at the Universities of Oporto and Pittsburgh.

“During my time at University and at Equigerminal, I noticed unusual anaemia and severe neurological signs in horses, which in my PhD I wrongly hypothesized to be attributed to Swamp Fever,” she said. “I then realised, through the samples, that this virus was actually closer to equine HIV – New Equine Virus, or NEV”.

After her discovery, Carvalho launched Equigerminal with fellow scientist Alexandre Vieira Pires.

“We have spent the last five years developing a diagnostic test and a potential cure for NEV.” explains Pires.“We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Nominations open for RCVS and VN Council elections

The nomination period for the 2026 RCVS Council and VN Council elections is now open, with three veterinary surgeon seats and two veterinary nurse seats available.

Prospective candidates can download an information pack and nomination form from the RCVS website. Individuals can nominate themselves for the elections, with the results to be announced in the spring.

Clare Paget, the recently appointed RCVS Registrar and elections returning officer, said: "If you want to play your part in influencing and moulding how the professions are regulated, and making key decisions on matters of great importance to your peers, the public and animal health and welfare, please consider standing for RCVS Council or VN Council next year."

Nominations close at 5pm on Saturday, 31 January 2026.